Labcorp has analyzed nearly 30,000 neurodegenerative clinical trial and study samples on the Quanterix™ platform and has expertise in running the following:

Biomarker Associated Diseases
NfL Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemperal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI
GFAP Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI
p-tau181 AD
Total tau Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI
Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau AD, HAND
Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NF-L and GFAP AD
Neuro 4-plex A: NF-L, GFAP, Total Tau, UCH-L1 Concussion/mTBI
a-synuclein PD, AD
Amyloid beta (1-42) AD
p-tau231 AD
Cytokine 3-plex: IL-6, TNFa, IL-10 AD (inflammation)

Want to learn more about biomarker solutions?

Visit the biomarker solutions section on Labcorp Drug Development to learn more about multi-disciplinary and integrated solutions to meet your biomarker strategy goals.

Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.


Finding a way to diagnose Alzheimer's earlier and easier is a key goal for Labcorp.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.